Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy

Chemotherapy-associated cardiotoxicity can present as a spectrum from arrhythmia to acute congestive heart failure. Unlike anthracyclines, proteasome inhibitors - for example, bortezomib - are not notorious for causing cardiotoxicity in absence of pre-existing cardiac dysfunction or without concomit...

Full description

Saved in:
Bibliographic Details
Published in:Journal of community hospital internal medicine perspectives 2015-01, Vol.5 (6), p.28982-3
Main Authors: Meseeha, Marcelle G, Kolade, Victor O, Attia, Maximos N
Format: Article
Language:English
Subjects:
Atherosclerosis
bortezomib
Cancer
Cancer therapies
Cardiology
Cardiomyopathy
cardiotoxicity
Cardiovascular disease
Case Report
Chemotherapy
Coronary vessels
Drug dosages
Family medical history
Funding
Heart attacks
Heart failure
Hospice care
Multiple myeloma
Patients
proteasome inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c450t-846517d1b62fe915c0ce313d76c46627d802b1e31004a8a23eb9a4219deac993
cites cdi_FETCH-LOGICAL-c450t-846517d1b62fe915c0ce313d76c46627d802b1e31004a8a23eb9a4219deac993
container_end_page 3
container_issue 6
container_start_page 28982
container_title Journal of community hospital internal medicine perspectives
container_volume 5
creator Meseeha, Marcelle G
Kolade, Victor O
Attia, Maximos N
description Chemotherapy-associated cardiotoxicity can present as a spectrum from arrhythmia to acute congestive heart failure. Unlike anthracyclines, proteasome inhibitors - for example, bortezomib - are not notorious for causing cardiotoxicity in absence of pre-existing cardiac dysfunction or without concomitant use of other cardiotoxic agents. We describe a 66-year-old woman with end-stage renal disease who developed acute dyspnea hours after a third treatment with bortezomib for IgG kappa myeloma. The Naranjo adverse drug reaction probability scale indicated a probable relationship (score of 5) between bortezomib and acute left ventricular dysfunction. Patients receiving proteasome inhibitors should be closely monitored for evidence of cardiac dysfunction during treatment.
doi_str_mv 10.3402/jchimp.v5.28982
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_7963729f649e479085a60bdc80edc56b</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_7963729f649e479085a60bdc80edc56b</doaj_id><sourcerecordid>3910651891</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-846517d1b62fe915c0ce313d76c46627d802b1e31004a8a23eb9a4219deac993</originalsourceid><addsrcrecordid>eNpVkc1P3DAQxSPUChDlzA1F6jnLxN_uoVKFWkBCag_cXcd2WK-SeGvHK9K_vobdIjjZnnn-zTy9qrpoYYUJoKuNWftxu9rRFRJSoKPqFAFAIxljH97cT6rzlDblBQxxAvi4OkGMUcwEO61-_9Jx9noYljq6nYvJd4OruxBn9zeMvmv8ZLNxtjY6Wh_m8OSNn5cvtZ7qPOWU9VBaObk69LU2eXYH5biErZ7Xy6fqY6-H5M4P51n18OP7w_Vtc__z5u76231jCIW5EYTRltu2Y6h3sqUGjMMttpwZwsreVgDq2lICIFpohF0nNUGttE4bKfFZdbfH2qA3ahv9qOOigvbqpRDio3o2aganuGSYI9kzIh3hEgTVDDprBDhrKOsK6-uetc3dWGpumqMe3kHfdya_Vo9hpwjjnAoogM8HQAx_skuz2oQcp2JftZxiQMUyL6qrvcrEkFJ0_euEFtRzwGofsNpR9RJw-XH5drFX_f848T-5LaTA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1753024507</pqid></control><display><type>article</type><title>Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy</title><source>NCBI_PubMed Central（免费）</source><source>Publicly Available Content (ProQuest)</source><source>Taylor &amp; Francis Open Access Journals</source><source>IngentaConnect Journals</source><creator>Meseeha, Marcelle G ; Kolade, Victor O ; Attia, Maximos N</creator><creatorcontrib>Meseeha, Marcelle G ; Kolade, Victor O ; Attia, Maximos N</creatorcontrib><description>Chemotherapy-associated cardiotoxicity can present as a spectrum from arrhythmia to acute congestive heart failure. Unlike anthracyclines, proteasome inhibitors - for example, bortezomib - are not notorious for causing cardiotoxicity in absence of pre-existing cardiac dysfunction or without concomitant use of other cardiotoxic agents. We describe a 66-year-old woman with end-stage renal disease who developed acute dyspnea hours after a third treatment with bortezomib for IgG kappa myeloma. The Naranjo adverse drug reaction probability scale indicated a probable relationship (score of 5) between bortezomib and acute left ventricular dysfunction. Patients receiving proteasome inhibitors should be closely monitored for evidence of cardiac dysfunction during treatment.</description><identifier>ISSN: 2000-9666</identifier><identifier>EISSN: 2000-9666</identifier><identifier>DOI: 10.3402/jchimp.v5.28982</identifier><identifier>PMID: 26653686</identifier><language>eng</language><publisher>United States: Greater Baltimore Medical Center</publisher><subject>Atherosclerosis ; bortezomib ; Cancer ; Cancer therapies ; Cardiology ; Cardiomyopathy ; cardiotoxicity ; Cardiovascular disease ; Case Report ; Chemotherapy ; Coronary vessels ; Drug dosages ; Family medical history ; Funding ; Heart attacks ; Heart failure ; Hospice care ; Multiple myeloma ; Patients ; proteasome inhibitors</subject><ispartof>Journal of community hospital internal medicine perspectives, 2015-01, Vol.5 (6), p.28982-3</ispartof><rights>Copyright Co-Action Publishing 2015</rights><rights>2015 Marcelle G. Meseeha et al. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-846517d1b62fe915c0ce313d76c46627d802b1e31004a8a23eb9a4219deac993</citedby><cites>FETCH-LOGICAL-c450t-846517d1b62fe915c0ce313d76c46627d802b1e31004a8a23eb9a4219deac993</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1753024507/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1753024507?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26653686$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Meseeha, Marcelle G</creatorcontrib><creatorcontrib>Kolade, Victor O</creatorcontrib><creatorcontrib>Attia, Maximos N</creatorcontrib><title>Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy</title><title>Journal of community hospital internal medicine perspectives</title><addtitle>J Community Hosp Intern Med Perspect</addtitle><description>Chemotherapy-associated cardiotoxicity can present as a spectrum from arrhythmia to acute congestive heart failure. Unlike anthracyclines, proteasome inhibitors - for example, bortezomib - are not notorious for causing cardiotoxicity in absence of pre-existing cardiac dysfunction or without concomitant use of other cardiotoxic agents. We describe a 66-year-old woman with end-stage renal disease who developed acute dyspnea hours after a third treatment with bortezomib for IgG kappa myeloma. The Naranjo adverse drug reaction probability scale indicated a probable relationship (score of 5) between bortezomib and acute left ventricular dysfunction. Patients receiving proteasome inhibitors should be closely monitored for evidence of cardiac dysfunction during treatment.</description><subject>Atherosclerosis</subject><subject>bortezomib</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Cardiology</subject><subject>Cardiomyopathy</subject><subject>cardiotoxicity</subject><subject>Cardiovascular disease</subject><subject>Case Report</subject><subject>Chemotherapy</subject><subject>Coronary vessels</subject><subject>Drug dosages</subject><subject>Family medical history</subject><subject>Funding</subject><subject>Heart attacks</subject><subject>Heart failure</subject><subject>Hospice care</subject><subject>Multiple myeloma</subject><subject>Patients</subject><subject>proteasome inhibitors</subject><issn>2000-9666</issn><issn>2000-9666</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpVkc1P3DAQxSPUChDlzA1F6jnLxN_uoVKFWkBCag_cXcd2WK-SeGvHK9K_vobdIjjZnnn-zTy9qrpoYYUJoKuNWftxu9rRFRJSoKPqFAFAIxljH97cT6rzlDblBQxxAvi4OkGMUcwEO61-_9Jx9noYljq6nYvJd4OruxBn9zeMvmv8ZLNxtjY6Wh_m8OSNn5cvtZ7qPOWU9VBaObk69LU2eXYH5biErZ7Xy6fqY6-H5M4P51n18OP7w_Vtc__z5u76231jCIW5EYTRltu2Y6h3sqUGjMMttpwZwsreVgDq2lICIFpohF0nNUGttE4bKfFZdbfH2qA3ahv9qOOigvbqpRDio3o2aganuGSYI9kzIh3hEgTVDDprBDhrKOsK6-uetc3dWGpumqMe3kHfdya_Vo9hpwjjnAoogM8HQAx_skuz2oQcp2JftZxiQMUyL6qrvcrEkFJ0_euEFtRzwGofsNpR9RJw-XH5drFX_f848T-5LaTA</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Meseeha, Marcelle G</creator><creator>Kolade, Victor O</creator><creator>Attia, Maximos N</creator><general>Greater Baltimore Medical Center</general><general>Co-Action Publishing</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20150101</creationdate><title>Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy</title><author>Meseeha, Marcelle G ; Kolade, Victor O ; Attia, Maximos N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-846517d1b62fe915c0ce313d76c46627d802b1e31004a8a23eb9a4219deac993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Atherosclerosis</topic><topic>bortezomib</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Cardiology</topic><topic>Cardiomyopathy</topic><topic>cardiotoxicity</topic><topic>Cardiovascular disease</topic><topic>Case Report</topic><topic>Chemotherapy</topic><topic>Coronary vessels</topic><topic>Drug dosages</topic><topic>Family medical history</topic><topic>Funding</topic><topic>Heart attacks</topic><topic>Heart failure</topic><topic>Hospice care</topic><topic>Multiple myeloma</topic><topic>Patients</topic><topic>proteasome inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Meseeha, Marcelle G</creatorcontrib><creatorcontrib>Kolade, Victor O</creatorcontrib><creatorcontrib>Attia, Maximos N</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database (ProQuest)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Journal of community hospital internal medicine perspectives</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Meseeha, Marcelle G</au><au>Kolade, Victor O</au><au>Attia, Maximos N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy</atitle><jtitle>Journal of community hospital internal medicine perspectives</jtitle><addtitle>J Community Hosp Intern Med Perspect</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>5</volume><issue>6</issue><spage>28982</spage><epage>3</epage><pages>28982-3</pages><issn>2000-9666</issn><eissn>2000-9666</eissn><abstract>Chemotherapy-associated cardiotoxicity can present as a spectrum from arrhythmia to acute congestive heart failure. Unlike anthracyclines, proteasome inhibitors - for example, bortezomib - are not notorious for causing cardiotoxicity in absence of pre-existing cardiac dysfunction or without concomitant use of other cardiotoxic agents. We describe a 66-year-old woman with end-stage renal disease who developed acute dyspnea hours after a third treatment with bortezomib for IgG kappa myeloma. The Naranjo adverse drug reaction probability scale indicated a probable relationship (score of 5) between bortezomib and acute left ventricular dysfunction. Patients receiving proteasome inhibitors should be closely monitored for evidence of cardiac dysfunction during treatment.</abstract><cop>United States</cop><pub>Greater Baltimore Medical Center</pub><pmid>26653686</pmid><doi>10.3402/jchimp.v5.28982</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2000-9666
ispartof Journal of community hospital internal medicine perspectives, 2015-01, Vol.5 (6), p.28982-3
issn 2000-9666
2000-9666
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_7963729f649e479085a60bdc80edc56b
source NCBI_PubMed Central（免费）; Publicly Available Content (ProQuest); Taylor & Francis Open Access Journals; IngentaConnect Journals
subjects Atherosclerosis
bortezomib
Cancer
Cancer therapies
Cardiology
Cardiomyopathy
cardiotoxicity
Cardiovascular disease
Case Report
Chemotherapy
Coronary vessels
Drug dosages
Family medical history
Funding
Heart attacks
Heart failure
Hospice care
Multiple myeloma
Patients
proteasome inhibitors
title Partially reversible bortezomib-induced cardiotoxicity: an unusual cause of acute cardiomyopathy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T04%3A13%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Partially%20reversible%20bortezomib-induced%20cardiotoxicity:%20an%20unusual%20cause%20of%20acute%20cardiomyopathy&rft.jtitle=Journal%20of%20community%20hospital%20internal%20medicine%20perspectives&rft.au=Meseeha,%20Marcelle%20G&rft.date=2015-01-01&rft.volume=5&rft.issue=6&rft.spage=28982&rft.epage=3&rft.pages=28982-3&rft.issn=2000-9666&rft.eissn=2000-9666&rft_id=info:doi/10.3402/jchimp.v5.28982&rft_dat=%3Cproquest_doaj_%3E3910651891%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c450t-846517d1b62fe915c0ce313d76c46627d802b1e31004a8a23eb9a4219deac993%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1753024507&rft_id=info:pmid/26653686&rfr_iscdi=true